Bristol-Myers Squibb
Develops medicines for cancer, blood disorders, immunology, cardiovascular disease and neuroscience.
$66.60
After-hours close+0.03 (+0.05%)
At close$66.57(−0.57%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $1.68 | — | — |
| Jul 2026 | $1.60 | $2.04 | +27.5% |
| Apr 2026 | $1.42 | $1.58 | +11.3% |
| Feb 2026 | $1.23 | $1.26 | +2.4% |
| Oct 2025 | $1.52 | $1.63 | +7.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | $1.68 | — | — | $12.59B | — | — |
| Jul 30, 2026 | $1.60 | $2.04 | +27.5% | $11.74B | $12.97B | +10.5% |
| Apr 30, 2026 | $1.42 | $1.58 | +11.3% | $10.93B | $11.49B | +5.1% |
| Feb 5, 2026 | $1.23 | $1.26 | +2.4% | $12.28B | $12.50B | +1.8% |
| Oct 30, 2025 | $1.52 | $1.63 | +7.2% | $11.85B | $12.22B | +3.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Jul 31, 2025 | ||||||
| Apr 24, 2025 | ||||||
| Feb 6, 2025 | ||||||
| Oct 31, 2024 | ||||||
| Jul 26, 2024 | ||||||
| Apr 25, 2024 | ||||||
| Feb 2, 2024 | ||||||
| Oct 26, 2023 | ||||||
| Jul 27, 2023 | ||||||
| Apr 27, 2023 | ||||||
| Feb 2, 2023 | ||||||
| Oct 25, 2022 | ||||||
| Jul 27, 2022 | ||||||
| Apr 29, 2022 | ||||||
| Feb 4, 2022 | ||||||
| Oct 27, 2021 | ||||||
| Jul 28, 2021 | ||||||
| Apr 29, 2021 | ||||||
| Feb 4, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 6, 2020 | ||||||
| May 7, 2020 | ||||||
| Feb 6, 2020 | ||||||
| Oct 31, 2019 | ||||||
| Jul 25, 2019 | ||||||
| Apr 25, 2019 | ||||||
| Jan 24, 2019 | ||||||
| Oct 25, 2018 | ||||||
| Jul 26, 2018 | ||||||
| Apr 26, 2018 | ||||||
| Feb 5, 2018 | ||||||
| Oct 26, 2017 | ||||||
| Jul 27, 2017 | ||||||
| Apr 27, 2017 | ||||||
| Jan 26, 2017 | ||||||
| Oct 27, 2016 | ||||||
| Jul 28, 2016 | ||||||
| Apr 28, 2016 | ||||||
| Jan 28, 2016 | ||||||
| Oct 27, 2015 | ||||||
| Jul 23, 2015 | ||||||